MX2022013920A - Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. - Google Patents

Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.

Info

Publication number
MX2022013920A
MX2022013920A MX2022013920A MX2022013920A MX2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A
Authority
MX
Mexico
Prior art keywords
antibodies
associated antigen
tumor associated
antigen antibodies
antigen
Prior art date
Application number
MX2022013920A
Other languages
English (en)
Spanish (es)
Inventor
Minghan Wang
Hui Zou
Haiqun Jia
Huiwen Wu
Original Assignee
Phanes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc
Publication of MX2022013920A publication Critical patent/MX2022013920A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
MX2022013920A 2020-05-07 2021-05-06 Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. MX2022013920A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063021215P 2020-05-07 2020-05-07
US202062706131P 2020-08-03 2020-08-03
US202063198420P 2020-10-16 2020-10-16
US202063131394P 2020-12-29 2020-12-29
PCT/US2021/031055 WO2021226321A2 (en) 2020-05-07 2021-05-06 Anti-tumor associated antigen antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2022013920A true MX2022013920A (es) 2022-11-30

Family

ID=78468388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013920A MX2022013920A (es) 2020-05-07 2021-05-06 Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.

Country Status (11)

Country Link
US (1) US20230220107A1 (https=)
EP (1) EP4146702A4 (https=)
JP (1) JP7821121B2 (https=)
KR (1) KR20230007452A (https=)
CN (1) CN115515981A (https=)
AU (1) AU2021267893A1 (https=)
BR (1) BR112022020716A2 (https=)
CA (1) CA3173176A1 (https=)
IL (1) IL297955A (https=)
MX (1) MX2022013920A (https=)
WO (1) WO2021226321A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
TW202426058A (zh) * 2022-10-18 2024-07-01 加拿大商酵活英屬哥倫比亞有限公司 靶向磷脂醯肌醇蛋白聚糖－３之抗體－藥物結合物及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
ME02345B (me) * 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
EP2699603B1 (en) * 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TW201713700A (zh) * 2015-05-27 2017-04-16 台灣泰福生技股份有限公司 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途
US11072666B2 (en) * 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11767362B1 (en) * 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
US11299708B2 (en) * 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
UA128383C2 (uk) * 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
EP3615574A4 (en) * 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
WO2019059411A1 (en) * 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
CN111040036B (zh) * 2018-10-12 2023-10-20 上海卡智生物技术有限公司 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用

Also Published As

Publication number Publication date
AU2021267893A1 (en) 2022-11-03
US20230220107A1 (en) 2023-07-13
JP7821121B2 (ja) 2026-02-26
WO2021226321A2 (en) 2021-11-11
IL297955A (en) 2023-01-01
EP4146702A2 (en) 2023-03-15
CN115515981A (zh) 2022-12-23
WO2021226321A3 (en) 2021-12-16
CA3173176A1 (en) 2021-11-11
JP2023525991A (ja) 2023-06-20
EP4146702A4 (en) 2024-07-10
BR112022020716A2 (pt) 2022-11-29
KR20230007452A (ko) 2023-01-12

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
ZA202006318B (en) Anti-dll3 antibodies and uses thereof
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
WO2021227307A8 (zh) 抗cd73抗体及其用途
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
ZA202302392B (en) Antibodies against ilt2 and use thereof
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
MX2024011805A (es) Nuevos anticuerpos anti-fgfr2
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
MX2024009726A (es) Anticuerpos anti-il13ra2 y usos de estos.
WO2023177974A3 (en) Anti-mesothelin antibodies and uses thereof
WO2024182475A3 (en) Anti-ror2 antibodies and uses thereof